The primary goals in the management of hypertension, angina pectoris, and postinfarction cases are to prevent further damage to the cardiovascular system and to reduce the risk of subsequent myocardial infarction. Of all the drugs currently available, the (β-blockers seem the most likely to achieve this aim. The search for new β-blockers centers around the need for agents that offer the advantages of (β-adrenoceptor antagonism with out the unwanted β1 effects, which may be dangerous in asthmatic patients and may make bronchitis, diabetes, and arteriopathy worse or more difficult to control. One solution is to use a selective β1-adrenoceptor antagonist. Another is to develop a molecule that acts as an antagonist at β1-adrenoceptors and as an agonist at β2-adrenoceptors. Celiprolol is such a “third-generation” β-blocker in that it combines both attributes, and thereby offers a clinically relevant advance. It does not seem to disrupt glucose homeostasis or exacerbate peripheral vascular disease, the lipid profile appears to be positively altered, and the risk of bronchospasm is reduced. Celiprolol is therefore both clinically and biochemically well tolerated.
No takes yet. Share an insight, caveat, or question.
M. J. Kendall (1989) studied this question.